REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights [Yahoo! Finance]
REGENXBIO Inc. (RGNX)
Last regenxbio inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.regenxbio.com
Company Research
Source: Yahoo! Finance
Dose level 2 selected as pivotal dose for RGX-202 treatment of Duchenne New positive interim efficacy and safety data announced for second boy at DL2 AFFINITY DUCHENNE ® trial expansion phase is underway with third and fourth boys dosed at DL2 End-of-Phase II meeting with FDA planned for early Q3 and pivotal trial initiation anticipated in late Q3 to early Q4 2024 Positive interim results from ALTITUDE ® trial for diabetic retinopathy support plans for anticipated End-of-Phase II meeting with FDA in Q1 2025 $381 million in cash, cash equivalents and marketable securities as of March 31, 2024 , expected to fund operational runway into 2026 Conference call Wednesday, May 8 , at 4:30 p.m. ET ROCKVILLE, Md. May 8, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced financial results for the first quarter ending March 31, 2024 . Recent operational highlights, including acceleration of the prioritized pipeline supports meaningful value generation from the Compa
Show less
Read more
Impact Snapshot
Event Time:
RGNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RGNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RGNX alerts
High impacting REGENXBIO Inc. news events
Weekly update
A roundup of the hottest topics
RGNX
News
- REGENXBIO Inc. (NASDAQ: RGNX) had its price target raised by analysts at HC Wainwright from $36.00 to $38.00. They now have a "buy" rating on the stock.MarketBeat
- Analysts Have Lowered Expectations For REGENXBIO Inc. (NASDAQ:RGNX) After Its Latest Results [Yahoo! Finance]Yahoo! Finance
- REGENXBIO to Participate in Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- REGENXBIO to Participate in Upcoming Investor ConferencesPR Newswire
- REGENXBIO Inc. (NASDAQ:RGNX) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
RGNX
Earnings
- 5/8/24 - Miss
RGNX
Sec Filings
- 5/16/24 - Form 4
- 5/14/24 - Form 144
- 5/8/24 - Form 10-Q
- RGNX's page on the SEC website